(Reuters) – Shares of Edwards Lifesciences Corp jumped 13 percent on Monday after a U.S. court temporarily halted sales of competitor Medtronic Inc’s heart valve implant that uses a less-invasive procedure to spare patients from open-heart surgery.
The ruling, by a U.S. District Court in Delaware on Friday, came after earlier court decisions that found Medtronic’s CoreValve infringed on Edwards’ Sapien transcatheter valve product.
